Why did Novartis keep its scandal to itself? Who knew what and when? And is there such thing as too much Peloton time?
We discuss all that and more on the latest episode of “The Readout LOUD,” STAT’s biotech podcast. We went all Novartis this week, explaining the shocking news that the Swiss pharma giant submitted falsified data to the FDA and then waited three months to inform regulators. We discuss what we know, what remains unanswered, the implications for Novartis’s corporate rebrand, and why this was awkward timing for Vas Narasimhan, the company’s ascendant CEO.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email firstname.lastname@example.org.
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at email@example.com.